Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Advanced glycation end product accumulation in the cardiomyocytes of heart failure patients with and without diabetes.

Nożyński J, Zakliczyński M, Konecka-Mrowka D, Zielinska T, Zakliczynska H, Nikiel B, Mlynarczyk-Liszka J, Mrowka A, Zembala-Nozynska E, Pijet M, Rdzanowska K, Lange D, Przybylski R, Zembala M.

Ann Transplant. 2012 Apr-Jun;17(2):53-61.

PMID:
22743723
2.

Advanced glycation end products in the development of ischemic and dilated cardiomyopathy in patients with diabetes mellitus type 2.

Nozyński J, Zakliczyński M, Konecka-Mrówka D, Nikiel B, Mlynarczyk-Liszka J, Zembala-Nozyńska E, Lange D, Maruszewski M, Zembala M.

Transplant Proc. 2009 Jan-Feb;41(1):99-104. doi: 10.1016/j.transproceed.2008.09.065.

PMID:
19249488
3.

Advanced glycation end-products in myocardium-supported vessels: effects of heart failure and diabetes mellitus.

Nożyński J, Zakliczyński M, Konecka-Mrówka D, Przybylski R, Zembala M, Zielińska T, Mrówka A, Lange D, Zembala-Nożyńska E, Nikiel B, Młynarczyk-Liszka J.

J Heart Lung Transplant. 2011 May;30(5):558-64. doi: 10.1016/j.healun.2010.11.006. Epub 2011 Jan 6.

PMID:
21212000
4.

Advanced glycation end products and lipofuscin deposits share the same location in cardiocytes of the failing heart.

Nozynski J, Zakliczynski M, Konecka-Mrowka D, Zakliczynska H, Pijet M, Zembala-Nozynska E, Lange D, Zembala M.

Exp Gerontol. 2013 Feb;48(2):223-8. doi: 10.1016/j.exger.2012.09.002. Epub 2012 Sep 12.

PMID:
22982091
5.

Regional heterogeneity of decreased myocardial norepinephrine and increased lipid peroxidation levels in patients with end-stage failing heart secondary to dilated or ischemic cardiomyopathy.

Rochette L, Tatou E, Vergely C, Maupoil V, Bouchot O, Mossiat C, Jazayeri S, Benkhadra S, Brenot R, Girard C, David M.

J Heart Lung Transplant. 2008 Jul;27(7):767-74. doi: 10.1016/j.healun.2008.03.025. Epub 2008 Jun 2.

PMID:
18582807
6.

[Nuclear changes and p62 expression in ischemic and dilated cardiomyopathy].

Cortés R, Portolés M, Roselló-Lletí E, Martínez-Dolz L, Almenar L, Salvador A, Rivera M.

Rev Esp Cardiol. 2007 Dec;60(12):1319-23. Spanish.

7.

The spatial pattern of coronary capillaries in patients with dilated, ischemic, or inflammatory cardiomyopathy.

Karch R, Neumann F, Ullrich R, Neumüller J, Podesser BK, Neumann M, Schreiner W.

Cardiovasc Pathol. 2005 May-Jun;14(3):135-44.

PMID:
15914298
8.

Regional mapping of myocardial hibernation phenotype in idiopathic end-stage dilated cardiomyopathy.

Lionetti V, Matteucci M, Ribezzo M, Di Silvestre D, Brambilla F, Agostini S, Mauri P, Padeletti L, Pingitore A, Delsedime L, Rinaldi M, Recchia FA, Pucci A.

J Cell Mol Med. 2014 Mar;18(3):396-414. doi: 10.1111/jcmm.12198. Epub 2014 Jan 20.

9.

Cardiomyocyte apoptosis and progression of heart failure to transplantation.

Saraste A, Pulkki K, Kallajoki M, Heikkilä P, Laine P, Mattila S, Nieminen MS, Parvinen M, Voipio-Pulkki LM.

Eur J Clin Invest. 1999 May;29(5):380-6.

PMID:
10354194
10.

Selective upregulation of cardiac endothelin system in patients with ischemic but not idiopathic dilated cardiomyopathy: endothelin-1 system in the human failing heart.

Serneri GG, Cecioni I, Vanni S, Paniccia R, Bandinelli B, Vetere A, Janming X, Bertolozzi I, Boddi M, Lisi GF, Sani G, Modesti PA.

Circ Res. 2000 Mar 3;86(4):377-85.

11.

Sarcoplasmic reticulum Ca2+ATPase and phospholamban mRNA and protein levels in end-stage heart failure due to ischemic or dilated cardiomyopathy.

Flesch M, Schwinger RH, Schnabel P, Schiffer F, van Gelder I, Bavendiek U, Südkamp M, Kuhn-Regnier F, Böhm M.

J Mol Med (Berl). 1996 Jun;74(6):321-32.

PMID:
8862513
12.

Enhanced bioactive myocardial transforming growth factor-β in advanced human heart failure.

Khan S, Joyce J, Margulies KB, Tsuda T.

Circ J. 2014;78(11):2711-8. Epub 2014 Oct 9.

14.

Apoptosis in myocytes in end-stage heart failure.

Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, Schmidt U, Semigran MJ, Dec GW, Khaw BA.

N Engl J Med. 1996 Oct 17;335(16):1182-9.

15.

Gap junction remodelling in human heart failure is associated with increased interaction of connexin43 with ZO-1.

Bruce AF, Rothery S, Dupont E, Severs NJ.

Cardiovasc Res. 2008 Mar 1;77(4):757-65. Epub 2007 Dec 4.

PMID:
18056766
16.

Desmin-free cardiomyocytes and myocardial dysfunction in end stage heart failure.

Di Somma S, Di Benedetto MP, Salvatore G, Agozzino L, Ferranti F, Esposito S, La Dogana P, Scarano MI, Caputo G, Cotrufo M, Santo LD, de Divitiis O.

Eur J Heart Fail. 2004 Jun;6(4):389-98.

17.

Functional networks of nucleocytoplasmic transport-related genes differentiate ischemic and dilated cardiomyopathies. A new therapeutic opportunity.

Molina-Navarro MM, Triviño JC, Martínez-Dolz L, Lago F, González-Juanatey JR, Portolés M, Rivera M.

PLoS One. 2014 Aug 19;9(8):e104709. doi: 10.1371/journal.pone.0104709. eCollection 2014 Aug 19.

18.

Impact of cardiac transplantation on molecular pathology of ET-1, VEGF-C, and mitochondrial metabolism and morphology in dilated versus ischemic cardiomyopathic patients.

Aharinejad S, Schäfer R, Hofbauer R, Abraham D, Blumer R, Miksovsky A, Traxler H, Pullirsch D, Alexandrowicz R, Taghavi S, Kocher A, Laufer G.

Transplantation. 2001 Sep 27;72(6):1043-9.

PMID:
11579298
19.

Different role of advanced glycation end products in pathology of transplanted heart in patients with or without diabetes mellitus type 2.

Zakliczynski M, Nozynski J, Konecka-Mrowka D, Pyka L, Trybunia D, Nikiel B, Mlynarczyk-Liszka J, Lange D, Zembala M.

Transplant Proc. 2009 Oct;41(8):3185-9. doi: 10.1016/j.transproceed.2009.07.069.

PMID:
19857706
20.

Increased Ca2+ sensitivity of myofibrillar tension in ischaemic vs dilated cardiomyopathy.

Lee S, Lu R, Müller-Ehmsen J, Schwinger RH, Brixius K.

Clin Exp Pharmacol Physiol. 2010 Dec;37(12):1134-8. doi: 10.1111/j.1440-1681.2010.05443.x.

PMID:
20804510

Supplemental Content

Support Center